More Cherished Moments
Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.
Search
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Driving Innovation through Diversity & Inclusion
Driving innovation through diversity and inclusion. Inclusive leaders and an inclusive organisation allow diversity to flourish. Diversity is the mix. Inclusion is making the mix work.
Championing life-science innovators and entrepreneurs
The Boehringer Ingelheim partnering team talks about Grass Roots innovation and the programs that are available to support life-science innovators.
We nurture innovative ideas
At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
A passion for research which addresses unmet medical needs
Eric Haaksma, Head of Global Innovation Animal Health, explains why his professional purpose is rooted in helping drive advancements in scientific research
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Partnering with Constantia Flexibles for augmented reality
Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Martin Stefanic
Learn how Patient Safety is at the cutting edge of innovation.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
We’re All In
Watch our video to learn about our approach to innovation and partnerships
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Eugene Zalmover
Learn how Eugene’s work paved the way for digital innovation in Patient Safety.
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Boehringer Ingelheim Academy Video 2023
Boehringer Ingelheim’s Academy initiative provides networking opportunities, education and facilitates conversations across the innovation community.
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Where to meet us
Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine